Table 3.
The specific characteristics and therapy efficacy of UABD nanomedicines
| Nanomedicines | Cavitation materials | Drugs | Particle size (nm) | tumors | Therapeutic effect | Refs |
|---|---|---|---|---|---|---|
| Liposomal Doxorubicin | MBs | Doxorubicin | ∼100 | Glioma | Survival time increased by 24% | [120] |
| PEG-AuNPs | – | Gold nanoparticle | 50 | – | – | [121] |
| MNBs | NBs | – | 500 | – | – | [122] |
| TMZ−NB@PLN−AAp | NBs | Temozolomide | 400.3 ± 4.7 | Glioblastoma | TIR: ~ 90% | [123] |
| DOX-CLs |
Lipidosome (MBs) |
Doxorubicin | ≈180 | Glioma | Survival extended to 81.2 days | [124] |
| PTX-LIPO |
Lipidosome (MBs) |
Paclitaxel | 98.3 | Glioma | Survival time increased by 20.8% | [125] |
| Albumin-Gd-DTPA | MBs | Gd | – | – | MR image enhancement; detect cerebral hemorrhage | [126] |
| Lipidosome-doxorubicin |
Lipidosome (MBs) |
Doxorubicin | ≈100 | Glioma | – | [127] |
| LPHNspCas9/MGMT-cRGD | MBs | CRISPR/Cas9 | 179.6 ± 44.82 | Glioma | Inhibit tumor growth and prolong the survival time of tumor-bearing mice | [128] |
| OFP and DFB droplets | PFCNDs | Proteins | 171 /183 | – | Successful delivery of 40 kDa dextran | [129] |
| Cationic nanodroplets | PFCNDs | Gene | 300–400 | – | Gene transfection efficiency was enhanced 14-fold on HepG2 cells | [130] |
| Acoustically-activated nanodroplets | PFCNDs | Dextran | 200–300 | – | Up to 33% of the animals showed a fluorescence enhancement | [44] |